Company profile PCVX

Vaxcyte Inc
sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-...spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe Show More
Quarter analysis & expected interestLast update: February 09 2024 19:12:41.

After 39 days of this quarter the interest is at 88.0. Based on that we can calculate that during remaining 52 days it will total up to 205.0.
Vaxcyte stock expected interest is significantly higher compared to previous quarter (+606.9%) and same quarter last year (+109.2%).

YearQ1Q2Q3Q4
201954
80
48.1% QoQ
66
-17.5% QoQ
24
-63.6% QoQ
2020 32
-40.7% YoY 33.3% QoQ
201
151.2% YoY 528.1% QoQ
141
113.6% YoY -29.9% QoQ
80
233.3% YoY -43.3% QoQ
2021 26
-18.8% YoY -67.5% QoQ
27
-86.6% YoY 3.8% QoQ
23
-83.7% YoY -14.8% QoQ
54
-32.5% YoY 134.8% QoQ
2022 91
250.0% YoY 68.5% QoQ
217
703.7% YoY 138.5% QoQ
151
556.5% YoY -30.4% QoQ
223
313.0% YoY 47.7% QoQ
2023 98
7.7% YoY -56.1% QoQ
237
9.2% YoY 141.8% QoQ
141
-6.6% YoY -40.5% QoQ
29
-87.0% YoY -79.4% QoQ
2024 88
-10.2% YoY 203.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Vaxcyte stock search interestLast update: February 09 2024 19:12:40.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 19:12:43.

The average 5 years interest of Vaxcyte stock was 7.98 per week.
The last year interest of Vaxcyte stock compared to the last 5 years has changed by 29.95%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 128.41%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Vaxcyte vaccine to provide analysis

Correlation between past revenue and Vaxcyte vaccine search interest

There is not enough data for Vaxcyte vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Vaxcyte vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Vaxcyte pneumococcal vaccine to provide analysis

Correlation between past revenue and Vaxcyte pneumococcal vaccine search interest

There is not enough data for Vaxcyte pneumococcal vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Vaxcyte pneumococcal vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Vaxcyte bacterial diseases to provide analysis

Correlation between past revenue and Vaxcyte bacterial diseases search interest

There is not enough data for Vaxcyte bacterial diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Vaxcyte bacterial diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-24 vaccine to provide analysis

Correlation between past revenue and VAX-24 vaccine search interest

There is not enough data for VAX-24 vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-24 vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-31 vaccine to provide analysis

Correlation between past revenue and VAX-31 vaccine search interest

There is not enough data for VAX-31 vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-31 vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-A1 vaccine to provide analysis

Correlation between past revenue and VAX-A1 vaccine search interest

There is not enough data for VAX-A1 vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-A1 vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-PG vaccine to provide analysis

Correlation between past revenue and VAX-PG vaccine search interest

There is not enough data for VAX-PG vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-PG vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-GI vaccine to provide analysis

Correlation between past revenue and VAX-GI vaccine search interest

There is not enough data for VAX-GI vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-GI vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PCVX
Earnings date: 2024-02-26 After close
Company name: Vaxcyte Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-06T20:05:00Z

GlobeNewswire
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

2026-04-07T20:05:00Z

GlobeNewswire
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-25T11:30:00Z

GlobeNewswire
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

2026-03-23T12:30:00Z

GlobeNewswire
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

2026-02-26T11:20:24Z

Analyst Upgrades
BTIG Maintains Buy on Vaxcyte, Raises Price Target to $89

2026-02-24T21:05:00Z

GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-02-11T21:05:00Z

GlobeNewswire
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

2026-02-10T21:05:00Z

GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

2026-02-05T21:05:00Z

GlobeNewswire
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

2026-02-02T21:05:00Z

GlobeNewswire
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-02-02T14:34:40Z

Analyst Upgrades
Guggenheim Reiterates Buy on Vaxcyte, Maintains $116 Price Target

2026-01-30T04:33:04Z

GlobeNewswire
Vaxcyte Announces Pricing of $550 Million Public Offering

2026-01-29T21:06:47Z

GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-01-22T22:00:00Z

GlobeNewswire
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

2026-01-07T11:23:09Z

Analyst Upgrades
Needham Maintains Buy on Vaxcyte, Raises Price Target to $110